CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 28 enrolled
Drug / intervention
Exenatidedrug
Likely dose
Exenatide 5 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00623545
NCT00623545Phase 4Completed
CompareCT.gov

Bioenergetic Alterations After Exenatide Administration

University of Wisconsin, Madison·interventional·Posted Feb 26, 2008·Updated Jan 9, 2015

In Brief

A Phase 4 clinical trial evaluating Exenatide for Healthy. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The purpose of this study is to find out how exenatide causes weight loss. Specifically, the study is assessing how exenatide may change how people take in energy (energy intake), as well as how it may effect how people use energy (energy expenditure).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 26, 2008
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.3 years ago

Interventions

Exenatidedrug

Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.